Oriol Roca

Oriol Roca

Auto-generated profile, based on publicly available information

Oriol Roca

Servei de Medicina Intensiva, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
OROriol Roca
Oriol Roca
BCBerta Caralt
Berta Caralt
JMJonathan Messika
Jonathan Messika
MSManuel Samper
Manuel Samper
BSBenjamin Sztrymf
Benjamin Sztrymf
JRJean-Damien Ricard
Jean-Damien Ricard
Rationale: One important concern during high-flow nasal cannula (HFNC) therapy in patients with acute hypoxemic respiratory failure is to not delay intubation. Objectives: To validate the diagnostic accuracy of an index (termed ROX and defined as the ratio of oxygen saturation as measured by pulse oximetry/Fi O2 to respiratory rate) for determining HFNC outcome (need or not for intubation). Methods: This was a 2-year multicenter prospective observational cohort study including patients with pneumonia treated with HFNC. Identification was through Cox proportional hazards modeling of ROX association with HFNC outcome. The most specific cutoff of the ROX index to predict HFNC failure and success was assessed. Measurements and Main Results: Among the 191 patients treated with HFNC in the validation cohort, 68 (35.6%) required intubation. The prediction accuracy of the ROX index increased over time (area under the receiver operating characteristic curve: 2 h, 0.679; 6 h, 0.703; 12 h, 0.759). ROX greater than or equal to 4.88 measured at 2 (hazard ratio, 0.434; 95% confidence interval, 0.264–0.715; P = 0.001), 6 (hazard ratio, 0.304; 95% confidence interval, 0.182–0.509; P < 0.001), or 12 hours (hazard ratio, 0.291; 95% confidence interval, 0.161–0.524; P < 0.001) after HFNC initiation was consistently associated with a lower risk for intubation. A ROX less than 2.85, less than 3.47, and less than 3.85 at 2, 6, and 12 hours of HFNC initiation, respectively, were predictors of HFNC failure. Patients who failed presented a lower increase in the values of the ROX index over the 12 hours. Among components of the index, oxygen saturation as measured by pulse oximetry/Fi O2 had a greater weight than respiratory rate. Conclusions: In patients with pneumonia with acute respiratory failure treated with HFNC, ROX is an index that can help identify those patients with low and those with high risk for intubation. Clinical trial registered with www.clinicaltrials.gov (NCT 02845128).

1 October 2016 in Journal of Critical Care
Verified
Journal Article
Closed access
OROriol Roca
Oriol Roca
JMJonathan Messika
Jonathan Messika
BCBerta Caralt
Berta Caralt
MGMarina García-De-Acilu
Marina García-De-Acilu
BSBenjamin Sztrymf
Benjamin Sztrymf
JMJoan R. Masclans
Joan R. Masclans

7 December 2017 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
CGClaude Guerin
Claude Guerin
SÑSilvio A. Ñamendys-Silva
Silvio A. Ñamendys-Silva
JCJ. M. Constantin
J. M. Constantin
GBG. Bellani
G. Bellani
PGP. Garcia-Olivares
P. Garcia-Olivares
TGthe ESICM Trials Group
the ESICM Trials Group

1 April 2010 in Respiratory Care
Verified
Journal Article
Closed access
OROriol Roca
Oriol Roca
JRJordi Riera
Jordi Riera
FTFerran Torres
Ferran Torres
JMJoan R Masclans
Joan R Masclans
OBJECTIVE:To compare the comfort of oxygen therapy via high-flow nasal cannula (HFNC) versus via conventional face mask in patients with acute respiratory failure. Acute respiratory failure was def...

1 April 2013 in Respiratory Care
Verified
Journal Article
Open access
PDF file
JRJordi Riera
Jordi Riera
PPPurificación Pérez
Purificación Pérez
Jordi CortésJordi Cortés
Jordi Cortés
OROriol Roca
Oriol Roca
JMJoan R Masclans
Joan R Masclans
JRJordi Rello
Jordi Rello
BACKGROUND: Electrical impedance tomography measures changes in lung impedance, which are mainly related to changes in lung volume. We used electrical impedance tomography to investigate the effects of high-flow nasal cannula (HFNC) and body position on global and regional end-expiratory lung impedance variation (ΔEELI). METHODS: Prospective study with 20 healthy adults. Two periods were defined: the first in supine position and the second in prone position. Each period was divided into 3 phases. In the first and the third phases the subjects were breathing ambient air, and in the second HFNC was implemented. Four regions of interest were defined: 2 ventral and 2 dorsal. For each respiratory cycle, global and regional ΔEELI were measured by electrical impedance tomography and were expressed as a function of the tidal variation of the first stable respiratory cycle (units). RESULTS: HFNC increased global EELI by 1.26 units (95% CI 1.20–1.31, P < .001) in supine position, and by 0.87 units (95% CI 0.82–0.91, P < .001) in prone position. The distribution of ΔEELI was homogeneous in prone position, with no difference between ventral and dorsal lung regions (−0.01 units, 95% CI −0.01 to 0, P = .18), while in supine position a significant difference was found (0.22 units, 95% CI 0.21–0.23, P < .001) with increased EELI in ventral areas. CONCLUSIONS: HFNC increased global EELI in our population, regardless of body position, suggesting an increase in functional residual capacity. Prone positioning was related to a more homogeneous distribution of ΔEELI, while in supine position ΔEELI was higher in the ventral lung regions.

28 April 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
F(for the Spanish Multidisciplinary Group of High Flow Supportive Therapy in Adults (HiSpaFlow)
for the Spanish Multidisciplinary Group of High Flow Supportive Therapy in Adults (HiSpaFlow)
OROriol Roca
Oriol Roca
GHGonzalo Hernández
Gonzalo Hernández
SDSalvador Díaz-Lobato
Salvador Díaz-Lobato
JCJosé M. Carratalá
José M. Carratalá
JMJoan R. Masclans
Joan R. Masclans
High flow nasal cannula (HFNC) supportive therapy has emerged as a safe, useful therapy in patients with respiratory failure, improving oxygenation and comfort. Recently several clinical trials have analyzed the effectiveness of HFNC therapy in different clinical situations and have reported promising results. Here we review the current knowledge about HFNC therapy, from its mechanisms of action to its effects on outcomes in different clinical situations.